Proactive Investors - Run By Investors For Investors

Abcam "back on track" Investec says

Investec said: “Abcam’s FY15 preliminary pre-close trading update shows that the business is back on track."
Abcam "back on track" Investec says
Abcam provides antibodies to pharma companies

Antibody supplier Abcam (LON:ABC) is “back on track” according to Investec.

The company expects its core catalogue products business to report growth of more than 16% to £136.8mln (£118mln)and see double digit improvement in all other product categories.

Abcam’s FY15 preliminary pre-close trading update shows that the business is back on track, delivering double-digit underlying revenue growth and expanding gross margins,” Investec said.

Alan Hirzel, chief executive, said: “Careful investment has driven growth in revenues and profits and Abcam is well placed for this to continue.”

Sales of Abcam’s RabMab technology, which develops monoclonal antibodies from rabbits instead of mice, grew by more than 24%.

Cannacord Genuity said the “strong” update meant revenues would be above its expectations.

The broker said it expects the “strong performance” to continue due to stability in underlying markets and “Abcam’s increased focus on the customer resulting in above market growth.”

Broker finnCap suggests total revenues could be in the region of £143mln, which would be ahead of its estimates of £137mln.

The gross margin is expected to be in line with the first half of the year (70.4%), compared with some analysts’ expectation of a decline to 70.1%.

Peel Hunt said: “The outperformance of the product business and the improvement in gross margin bode well for growth prospects.”

Shares rose 9.35% to just under 567p.

View full ABC profile View Profile

Abcam Timeline

January 10 2017

Related Articles

June 24 2019
Long-term fundamentals remain firmly in the seafood specialist's favour
tablets and pills
June 27 2019
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use